Literature DB >> 20367193

Current treatment and clinical trials in ovarian cancer.

Liz Y Han1, Emma Kipps, Stan B Kaye.   

Abstract

Although platinum chemotherapy remains the standard treatment for ovarian cancer, recent advances in novel targeted drugs have generated anticipation and excitement. In addition, alternate administration schedules of already established cytotoxics have shown promise in both front line and recurrent disease settings. In this review, we outline the seminal trials that influenced our current management as well as introduce recent trials that have provided intriguing results to aid the understanding of ovarian tumour biology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367193     DOI: 10.1517/13543781003647966

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  4 in total

1.  Impact of shifting from office- to hospital-based treatment facilities on the administration of intraperitoneal chemotherapy for ovarian cancer.

Authors:  William R Robinson; Julie Beyer
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

2.  Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

Authors:  Preetinder P Singh; Swapna Joshi; Pamela J Russell; Sham Nair; Aparajita Khatri
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

3.  The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest.

Authors:  Manuel D Haschka; Claudia Soratroi; Susanne Kirschnek; Georg Häcker; Richard Hilbe; Stephan Geley; Andreas Villunger; Luca L Fava
Journal:  Nat Commun       Date:  2015-04-29       Impact factor: 14.919

4.  Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models.

Authors:  Cong Zhou; Jiali Kang; Xiaoxia Wang; Wei Wei; Wenyan Jiang
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.